Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs

R Khanna1, S R Burrows, S A Thomson

  • 1Queensland Institute of Medical Research, The Bancroft Centre, Brisbane, Australia.

Journal of Immunology (Baltimore, Md. : 1950)
|April 15, 1997
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer.

ESMO open·2026
Same author

Dual-pumping supercontinuum generation and temporal reflection in a nonlinear photonic integrated circuit.

Optics express·2026
Same author

Effectiveness of Self-Help Interventions to Reduce Work Disability: A Rapid Mixed Methods Systematic Review.

Journal of occupational rehabilitation·2026
Same author

Scalable photonic reservoir computing for parallel machine learning tasks.

Nature communications·2025
Same author

Supercontinuum generation in high-index doped silica photonic integrated circuits under diverse pumping settings.

Optics express·2025
Same author

Therapeutic soundscapes - improving health and wellbeing with sonic art.

Perspectives in public health·2022

This study identifies CD4+ cytotoxic T lymphocytes (CTLs) targeting Epstein-Barr virus (EBV) epitopes presented by HLA-DQ2 and HLA-DQ7. These findings reveal a new strategy for immune targeting of EBV-positive malignancies like Burkitt's lymphoma.

Area of Science:

  • Immunology
  • Virology
  • Oncology

Background:

  • Epstein-Barr virus (EBV) is linked to malignancies, including Burkitt's lymphoma (BL).
  • BL cells evade immune detection by down-regulating peptide transporter genes, hindering class I-restricted T cell recognition.
  • Understanding alternative immune evasion and targeting mechanisms is crucial for treating EBV-associated cancers.

Purpose of the Study:

  • To investigate the potential of CD4+ T cells in recognizing EBV-infected cells, specifically Burkitt's lymphoma.
  • To explore the processing and presentation of EBV epitopes via the Major Histocompatibility Complex (MHC) class II pathway in BL cells.

Main Methods:

  • Isolation of CD4+ cytotoxic T lymphocytes (CTLs) recognizing an EBV nuclear antigen 2 epitope.
  • Analysis of epitope presentation by HLA-DQ2 and HLA-DQ7 alleles.

Related Experiment Videos

  • Assessment of BL cell recognition by EBV-specific CTLs after infection with recombinant vaccinia virus.
  • Evaluation of MHC class II expression and processing pathway components (CLIP, HLA-DMB) on BL cells.

    • Main Results:

    • CD4+ CTLs were identified that recognize an EBV epitope presented by both HLA-DQ2 and HLA-DQ7.
    • Burkitt's lymphoma cells were efficiently recognized by CD4+, MHC class II-restricted EBV-specific CTLs.
    • BL cells exhibited high surface expression of MHC class II molecules (HLA-DR, HLA-DQ) with low CLIP and normal HLA-DMB expression, indicating functional class II processing.

    Conclusions:

    • Burkitt's lymphoma cells can process and present EBV-derived epitopes via the MHC class II pathway.
    • This efficient class II processing pathway offers a novel mechanism for immune targeting of EBV-positive malignancies.
    • The findings suggest a potential therapeutic strategy for EBV-associated cancers by engaging CD4+ T cell responses.